Daily Stock Market News

LLY Stock Dives — Taking Novo, Sanofi With It — After Fake Twitter Account Promises Free


Elon Musk’s new pay-for-play verification system on Twitter shook pharmaceutical mainstay Eli Lilly (LLY) — leading LLY stock to skid Friday — after a fake account claimed “insulin is free now.”




X



The tweet went live around 1:30 p.m. on Thursday from an account claiming to be Eli Lilly. It remained online for several hours, gaining steam from hundreds of retweets and thousands of likes. As of Friday morning, the fake account is no longer verified and its tweets are now private.

But that didn’t stop LLY stock from falling 4.5% to 352.30 on today’s stock market. Health care stocks were broadly pummeled Friday as well.

“We apologize to those who have been served a misleading message from a fake Lilly account,” the company said from its official account.

The fake tweet is shown here:

LLY Stock Dive Extends To Rivals

Eli Lilly’s official account was verified under Twitter’s old rules. The new verification system allows any account to be verified for just $8 per month. The move has spurred numerous fake accounts to crop up, impersonating celebrities, politicians and historical figures.

Insulin prices have become a hot-button issue in the U.S. where no generics exist. Without insulin, some patients with diabetes would die. Lilly, Novo Nordisk (NVO) and Sanofi (SNY) supply 100% of the insulin used in the U.S. and 90% globally.

The LLY stock slide also extended to its rivals. Novo Nordisk shares fell 3.5% to 111.47. Sanofi stock lost 3.4% and ended the regular session at 42.80.

In the third quarter, alone, Lilly’s insulin products generated more than $878 million in sales. Sales fell more than 20% year over year, however. Lilly noted its Humalog brand insulin underwent price cuts during the quarter. On its website, Lilly offers a program in which insulin will cost $35 per month.

Representatives of the company didn’t immediately return a request for comment Friday morning.

LLY stock recently broke out of a flat base with a buy point at 335.43, according to MarketSmith.com. Shares are now beyond the 5% chase zone.

Follow Allison Gatlin on Twitter at @IBD_AGatlin.

YOU MAY ALSO LIKE:

Veru Stock Plummets 54% After FDA Advisors Vote Down Cancer-Turned-Covid Drug

How Dexcom’s ‘Biggest Ever’ Launch Is Reinvigorating Its Stock

IBD Stock Of The Day: See How To Find, Track And Buy The Best Stocks

Watch IBD’s Investing Strategies Show For Actionable Market Insights

Market Rally Gains Steam; 5 Stocks Near Buy Points





Read More: LLY Stock Dives — Taking Novo, Sanofi With It — After Fake Twitter Account Promises Free

You might also like
A note to our visitors

This website has updated its privacy policy in compliance with changes to European Union data protection law, for all members globally. We’ve also updated our Privacy Policy to give you more information about your rights and responsibilities with respect to your privacy and personal information. Please read this to review the updates about which cookies we use and what information we collect on our site. By continuing to use this site, you are agreeing to our updated privacy policy.